Top

Journal of Neuroinflammation

Published in:

Open Access 01-12-2018 | Research

Transcriptional profile and Epstein-Barr virus infection status of laser-cut immune infiltrates from the brain of patients with progressive multiple sclerosis

Authors: Caterina Veroni, Barbara Serafini, Barbara Rosicarelli, Corrado Fagnani, Francesca Aloisi

Published in: Journal of Neuroinflammation | Issue 1/2018

Abstract

Background

It is debated whether multiple sclerosis (MS) might result from an immunopathological response toward an active Epstein-Barr virus (EBV) infection brought into the central nervous system (CNS) by immigrating B cells. Based on this model, a relationship should exist between the local immune milieu and EBV infection status in the MS brain. To test this hypothesis, we analyzed expression of viral and cellular genes in brain-infiltrating immune cells.

Methods

Twenty-three postmortem snap-frozen brain tissue blocks from 11 patients with progressive MS were selected based on good RNA quality and prominent immune cell infiltration. White matter perivascular and intrameningeal immune infiltrates, including B cell follicle-like structures, were isolated from brain sections using laser capture microdissection. Enhanced PCR-based methods were used to investigate expression of 75 immune-related genes and 6 EBV genes associated with latent and lytic infection. Data were analyzed using univariate and multivariate statistical methods.

Results

Genes related to T cell activation, cytotoxic cell-mediated (or type 1) immunity, B cell growth and differentiation, pathogen recognition, myeloid cell function, type I interferon pathway activation, and leukocyte recruitment were found expressed at different levels in most or all MS brain immune infiltrates. EBV genes were detected in brain samples from 9 of 11 MS patients with expression patterns suggestive of in situ activation of latent infection and, less frequently, entry into the lytic cycle. Comparison of data obtained in meningeal and white matter infiltrates revealed higher expression of genes related to interferonγ production, B cell differentiation, cell proliferation, lipid antigen presentation, and T cell and myeloid cell recruitment, as well as more widespread EBV infection in the meningeal samples. Multivariate analysis grouped genes expressed in meningeal and white matter immune infiltrates into artificial factors that were characterized primarily by genes involved in type 1 immunity effector mechanisms and type I interferon pathway activation.

Conclusion

These results confirm profound in situ EBV deregulation and suggest orchestration of local antiviral function in the MS brain, lending support to a model of MS pathogenesis that involves EBV as possible antigenic stimulus of the persistent immune response in the central nervous system.

Available only for authorised users

Olsson T, Barcellos LF, Alfredsson L. Interactions between genetic, lifestyle and environmental risk factors for multiple sclerosis. Nat Rev Neurol. 2017;13:25–36. https://doi.org/10.1038/nrneurol.2016.187.CrossRefPubMed

Lassmann H, Brück W, Lucchinetti CF. The immunopathology of multiple sclerosis: an overview. Brain Pathol. 2007;17:210–8.CrossRefPubMed

Frischer JM, Bramow S, Dal-Bianco A, Lucchinetti CF, Rauschka H, Schmidbauer M, Laursen H, Sorensen PS, Lassmann H. The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain. 2009;132:1175–89. https://doi.org/10.1093/brain/awp070.CrossRefPubMedPubMedCentral

Mahad DH, Trapp BD, Lassmann H. Pathological mechanisms in progressive multiple sclerosis. Lancet Neurol. 2015;14:183–93. https://doi.org/10.1016/S1474-4422(14)70256-X.CrossRefPubMed

Prinz M, Priller J. The role of peripheral immune cells in the CNS in steady state and disease. Nat Neurosci. 2017;20:136–44. https://doi.org/10.1038/nn.4475.CrossRefPubMed

Serafini B, Rosicarelli B, Magliozzi R, Stigliano E, Aloisi F. Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol. 2004;14:164–74.CrossRefPubMed

Magliozzi R, Howell O, Vora A, Serafini B, Nicholas R, Puopolo M, Reynolds R, Aloisi F. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain. 2007;130:1089–104.CrossRefPubMed

Serafini B, Rosicarelli B, Magliozzi R, Stigliano E, Capello E, Mancardi GL, Aloisi F. Dendritic cells in multiple sclerosis lesions: maturation stage, myelin uptake, and interaction with proliferating T cells. J Neuropathol Exp Neurol. 2006;65:124–41.CrossRefPubMed

Ifergan I, Kébir H, Bernard M, Wosik K, Dodelet-Devillers A, Cayrol R, Arbour N, Prat A. The blood–brain barrier induces differentiation of migrating monocytes into Th17-polarizing dendritic cells. Brain. 2008;131:785–99.CrossRefPubMed

10.

Lande R, Gafa V, Serafini B, Giacomini E, Visconti A, Remoli ME, Severa M, Parmentier M, Ristori G, Salvetti M, Aloisi F, Coccia EM. Plasmacytoid dendritic cells in multiple sclerosis: intracerebral recruitment and impaired maturation in response to interferon-beta. J Neuropathol Exp Neurol. 2008;67:388–401. https://doi.org/10.1097/NEN.0b013e31816fc975.CrossRefPubMed

11.

Mayo L, Quintana FJ, Weiner HL. The innate immune system in demyelinating disease. Immunol Rev. 2012;248:170–87. https://doi.org/10.1111/j.1600-065X.2012.01135.x.CrossRefPubMedPubMedCentral

12.

Kaur G, Trowsdale J, Fugger L. Natural killer cells and their receptors in multiple sclerosis. Brain. 2013;136:2657–76. https://doi.org/10.1093/brain/aws159.CrossRefPubMed

13.

Annunziato F, Romagnani C, Romagnani S. The 3 major types of innate and adaptive cell-mediated effector immunity. J Allergy Clin Immunol. 2015;135:626–35. https://doi.org/10.1016/j.jaci.2014.11.001.CrossRefPubMed

14.

Lassmann H, Ransohoff R. The CD4-Th1 model for multiple sclerosis: a critical re-appraisal. Trends Immunol. 2004;25:132–7.CrossRefPubMed

15.

Serafini B, Rosicarelli B, Franciotta D, Magliozzi R, Reynolds R, Cinque P, Andreoni L, Trivedi P, Salvetti M, Faggioni A, Aloisi F. Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain. J Exp Med. 2007;204:2899–912.CrossRefPubMedPubMedCentral

16.

Gardner C, Magliozzi R, Durrenberger PF, Howell OW, Rundle J, Reynolds R. Cortical grey matter demyelination can be induced by elevated pro-inflammatory cytokines in the subarachnoid space of MOG-immunized rats. Brain. 2013;136:3596–608. https://doi.org/10.1093/brain/awt279.CrossRefPubMed

17.

Becher B, Spath S, Goverman J. Cytokine networks in neuroinflammation. Nat Rev Immunol. 2017;17:49–59. https://doi.org/10.1038/nri.2016.123.CrossRefPubMed

18.

Booss J, Esiri MM, Tourtellotte WW, Mason DY. Immunohistological analysis of T lymphocyte subsets in the central nervous system in chronic progressive multiple sclerosis. J Neurol Sci. 1983;62:219–32.CrossRefPubMed

19.

Hayashi T, Morimoto C, Burks JS, Kerr C, Hauser SL. Dual-label immunocytochemistry of the active multiple sclerosis lesion: major histocompatibility complex and activation antigens. Ann Neurol. 1988;24:523–31.CrossRefPubMed

20.

Babbe H, Roers A, Waisman A, Lassmann H, Goebels N, Hohlfeld R, Friese M, Schröder R, Deckert M, Schmidt S, Ravid R, Rajewsky K. Clonal expansions of CD8(+) T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction. J Exp Med. 2000;192:393–404.CrossRefPubMedPubMedCentral

21.

Denic A, Wootla B, Rodriguez M. CD8+ T cells in multiple sclerosis. Expert Opin Ther Targets. 2013;17:1053–66. https://doi.org/10.1517/14728222.2013.815726.CrossRefPubMedPubMedCentral

22.

van Nierop GP, van Luijn MM, Michels SS, Melief MJ, Janssen M, Langerak AW, Ouwendijk WJD, Hintzen RQ, Verjans GM. Phenotypic and functional characterization of T cells in white matter lesions of multiple sclerosis patients. Acta Neuropathol. 2017;134:383–401. https://doi.org/10.1007/s00401-017-1744-4.CrossRefPubMedPubMedCentral

23.

Bitsch A, Schuchardt J, Bunkowski S, Kuhlmann T, Brück W. Acute axonal injury in multiple sclerosis. Correlation with demyelination and inflammation. Brain. 2000;123:1174–83.CrossRefPubMed

24.

Sobottka B, Harrer MD, Ziegler U, Fischer K, Wiendl H, Hünig T, Becher B, Goebels N. Collateral bystander damage by myelin-directed CD8+ T cells causes axonal loss. Am J Pathol. 2009;17:1160–6. https://doi.org/10.2353/ajpath.2009.090340.CrossRef

25.

Noster R, Riedel R, Mashreghi MF, Radbruch H, Harms L, Haftmann C, Chang HD, Radbruch A, Zielinski CE. IL-17 and GM-CSF expression are antagonistically regulated by human T helper cells. Sci Transl Med. 2014;6:241ra80. https://doi.org/10.1126/scitranslmed.3008706.CrossRefPubMed

26.

Croxford AL, Spath S, Becher B. GM-CSF in neuroinflammation: licensing myeloid cells for tissue damage. Trends Immunol. 2015;36:651–62.CrossRefPubMed

27.

Rasouli J, Ciric B, Imitola J, Gonnella P, Hwang D, Mahajan K, Mari ER, Safavi F, Leist TP, Zhang GX, Rostami A. Expression of GM-CSF in T cells is increased in multiple sclerosis and suppressed by IFN-β therapy. J Immunol. 2015;194:5085–93. https://doi.org/10.4049/jimmunol.1403243.CrossRefPubMedPubMedCentral

28.

Mishra MK, Yong VW. Myeloid cells-targets of medication in multiple sclerosis. Nat Rev Neurol. 2016;12:539–51. https://doi.org/10.1038/nrneurol.2016.110.CrossRefPubMed

29.

Tzartos JS, Friese MA, Craner MJ, Palace J, Newcombe J, Esiri MM, Fugger L. Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. Am J Pathol. 2008;172:146–55.CrossRefPubMedPubMedCentral

30.

Kebir H, Kreymborg K, Ifergan I, Dodelet-Devillers A, Cayrol R, Bernard M, Giuliani F, Arbour N, Becher B, Prat A. Human TH17 lymphocytes promote blood–brain barrier disruption and central nervous system inflammation. Nat Med. 2007;13:1173–5.CrossRefPubMedPubMedCentral

31.

Kebir H, Ifergan I, Alvarez JI, Bernard M, Poirier J, Arbour N, Duquette P, Prat A. Preferential recruitment of interferon-gamma-expressing TH17 cells in multiple sclerosis. Ann Neurol. 2009;66:390–402. https://doi.org/10.1002/ana.21748.CrossRefPubMed

32.

Serafini B, Rosicarelli B, Veroni C, Zhou L, Reali C, Aloisi F. RORγt expression and lymphoid neogenesis in the brain of patients with secondary progressive multiple sclerosis. J Neuropathol Exp Neurol. 2016;75:877–88. https://doi.org/10.1093/jnen/nlw063.CrossRefPubMed

33.

Pikor NB, Prat A, Bar-Or A, Gommerman JL. Meningeal tertiary lymphoid tissues and multiple sclerosis: a gathering place for diverse types of immune cells during CNS autoimmunity. Front Immunol. 2016;6:657. https://doi.org/10.3389/fimmu.2015.00657.CrossRefPubMedPubMedCentral

34.

Planas R, Metz I, Ortiz Y, Vilarrasa N, Jelčić I, Salinas-Riester G, Heesen C, Brück W, Martin R, Sospedra M. Central role of Th2/Tc2 lymphocytes in pattern II multiple sclerosis lesions. Ann Clin Transl Neurol. 2015;2:875–93. https://doi.org/10.1002/acn3.218.CrossRefPubMedPubMedCentral

35.

Martin R, Sospedra M, Rosito M, Engelhardt B. Current multiple sclerosis treatments have improved our understanding of MS autoimmune pathogenesis. Eur J Immunol. 2016;46:2078–90. https://doi.org/10.1002/eji.201646485.CrossRefPubMed

36.

Wekerle H. B cells in multiple sclerosis. Autoimmunity. 2017;50:57–60. https://doi.org/10.1080/08916934.2017.1281914.CrossRefPubMed

37.

Giovannoni G, Cutter GR, Lunemann J, Martin R, Münz C, Sriram S, Steiner I, Hammerschlag MR, Gaydos CA. Infectious causes of multiple sclerosis. Lancet Neurol. 2006;5:887–94. https://doi.org/10.1016/S1474-4422(06)70577-4.CrossRefPubMed

38.

Ascherio A. Environmental factors in multiple sclerosis. Expert Rev Neurother. 2013;13:3–9. https://doi.org/10.1586/14737175.2013.865866.CrossRefPubMed

39.

Lünemann JD, Münz C. EBV in MS: guilty by association? Trends Immunol. 2009;30:243–8. https://doi.org/10.1016/j.it.2009.03.007.CrossRefPubMed

40.

Lucas RM, Hughes AM, Lay ML, Ponsonby AL, Dwyer DE, Taylor BV, Pender MP. Epstein-Barr virus and multiple sclerosis. J Neurol Neurosurg Psychiatry. 2011;82:1142–8. https://doi.org/10.1136/jnnp-2011-300174.CrossRefPubMed

41.

Taylor GS, Long HM, Brooks JM, Rickinson AB, Hislop AD. The immunology of Epstein-Barr virus-induced disease. Annu Rev Immunol. 2015;33:787–821. https://doi.org/10.1146/annurev-immunol-032414-112326.CrossRefPubMed

42.

Willis SN, Stadelmann C, Rodig SJ, Caron T, Gattenloehner S, Mallozzi SS, Roughan JE, Almendinger SE, Blewett MM, Brück W, Hafler DA, O'Connor KC. Epstein-Barr virus infection is not a characteristic feature of multiple sclerosis brain. Brain. 2009;132:3318–28. https://doi.org/10.1093/brain/awp200.CrossRefPubMedPubMedCentral

43.

Peferoen LA, Lamers F, Lodder LN, Gerritsen WH, Huitinga I, Melief J, Giovannoni G, Meier U, Hintzen RQ, Verjans GM, van Nierop GP, Vos W, Peferoen-Baert RM, Middeldorp JM, van der Valk P, Amor S. Epstein Barr virus is not a characteristic feature in the central nervous system in established multiple sclerosis. Brain. 2010;133:1–4. https://doi.org/10.1093/brain/awp296.CrossRef

44.

Sargsyan SA, Shearer AJ, Ritchie AM, Burgoon MP, Anderson S, Hemmer B, Stadelmann C, Gattenlöhner S, Owens GP, Gilden D, Bennett JL. Absence of Epstein-Barr virus in the brain and CSF of patients with multiple sclerosis. Neurology. 2010;74:1127–35. https://doi.org/10.1212/WNL.0b013e3181d865a1.CrossRefPubMedPubMedCentral

45.

Lassmann H, Niedobitek G, Aloisi F, Middeldorp JM; NeuroproMiSe EBV Working Group. Epstein-Barr virus in the multiple sclerosis brain: a controversial issue. Brain 2011;134:2772–2786. doi: https://doi.org/10.1093/brain/awr197.

46.

Serafini B, Severa M, Columba-Cabezas S, Rosicarelli B, Veroni C, Chiappetta G, Magliozzi R, Reynolds R, Coccia EM, Aloisi F. Epstein-Barr virus latent infection and BAFF expression in B-cells in the multiple sclerosis brain: implications for viral persistence and intrathecal B-cell activation. J Neuropath Exp Neurol. 2010;69:677–93. https://doi.org/10.1097/NEN.0b013e3181e332ec.CrossRefPubMed

47.

Serafini B, Muzio L, Rosicarelli B, Aloisi F. Radioactive in situ hybridization for EBER supports presence of Epstein-Barr virus in the multiple sclerosis brain. Brain. 2013;136:e233. https://doi.org/10.1093/brain/aws315.CrossRefPubMed

48.

Magliozzi R, Serafini B, Rosicarelli B, Chiappetta G, Veroni C, Reynolds R, Aloisi F. B-cell enrichment and Epstein-Barr virus infection in inflammatory cortical lesions in secondary progressive multiple sclerosis. J Neuropathol Exp Neurol. 2013;72:29–41. https://doi.org/10.1097/NEN.0b013e31827bfc62.CrossRefPubMed

49.

Angelini DF, Serafini B, Piras E, Severa M, Coccia EM, Rosicarelli B, Ruggieri S, Gasperini C, Buttari F, Centonze D, Mechelli R, Salvetti M, Borsellino G, Aloisi F, Battistini L. Increased CD8+ T cell response to Epstein-Barr virus lytic antigens in the active phase of multiple sclerosis. PLoS Pathog. 2013;9:e1003220. https://doi.org/10.1371/journal.ppat.1003220.CrossRefPubMedPubMedCentral

50.

Serafini B, Rosicarelli B, Aloisi F, Stigliano E. EBV in the central nervous system and cervical lymph node of a patient with primary progressive multiple sclerosis. J Neuropathol Exp Neurol. 2014;73:729–31. https://doi.org/10.1097/NEN.0000000000000082.CrossRefPubMed

51.

Veroni C, Marnetto F, Granieri L, Bertolotto A, Ballerini C, Repice AM, Schirru L, Coghe G, Cocco E, Anastasiadou E, Puopolo M, Aloisi F. Immune and Epstein-Barr virus gene expression in cerebrospinal fluid and peripheral blood mononuclear cells from patients with relapsing-remitting multiple sclerosis. J Neuroinflammation. 2015;12:132. https://doi.org/10.1186/s12974-015-0353-1.CrossRefPubMedPubMedCentral

52.

Magliozzi R, Howell OW, Reeves C, Roncaroli F, Nicholas R, Serafini B, Aloisi F, Reynolds R. A gradient of neuronal loss and meningeal inflammation in multiple sclerosis. Ann Neurol. 2010;68:477–93. https://doi.org/10.1002/ana.22230.CrossRefPubMed

53.

Howell OW, Reeves CA, Nicholas R, Carassiti D, Radotra B, Gentleman SM, Serafini B, Aloisi F, Roncaroli F, Magliozzi R, Reynolds R. Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis. Brain. 2011;134:2755–71. https://doi.org/10.1093/brain/awr182.CrossRefPubMed

54.

Pitzalis C, Jones GW, Bombardieri M, Jones SA. Ectopic lymphoid-like structures in infection, cancer and autoimmunity. Nat Rev Immunol. 2014;14:447–62. https://doi.org/10.1038/nri3700.CrossRefPubMed

55.

Iwakiri D, Takada K. Role of EBERs in the pathogenesis of EBV infection. Adv Cancer Res. 2010;107:119–36. https://doi.org/10.1016/S0065-230X(10)07004-1.CrossRefPubMed

56.

Unterholzner L. The interferon response to intracellular DNA: why so many receptors. Immunobiology. 2013;218:1312–21. https://doi.org/10.1016/j.imbio.2013.07.007.CrossRefPubMed

57.

Gerwien H, Hermann S, Zhang X, Korpos E, Song J, Kopka K, Faust A, Wenning C, Gross CC, Honold L, Melzer N, Opdenakker G, Wiendl H, Schäfers M, Sorokin L. Imaging matrix metalloproteinase activity in multiple sclerosis as a specific marker of leukocyte penetration of the blood–brain barrier. Sci Transl Med. 2016;8:364ra152.CrossRefPubMed

58.

Burrack KS, Morrison TE. The role of myeloid cell activation and arginine metabolism in the pathogenesis of virus-induced diseases. Front Immunol. 2014;5:428.CrossRefPubMedPubMedCentral

59.

Thorley-Lawson DA. Epstein-Barr virus: exploiting the immune system. Nat Rev Immunol. 2001;1:75–82.CrossRefPubMed

60.

Kang MS, Kieff E. Epstein-Barr virus latent genes. Exp Mol Med. 2015;47:e131. https://doi.org/10.1038/emm.2014.84.CrossRefPubMedPubMedCentral

61.

Laichalk LL, Thorley-Lawson DA. Terminal differentiation into plasma cells initiates the replicative cycle of Epstein-Barr virus in vivo. J Virol. 2005;79:1296–307.CrossRefPubMedPubMedCentral

62.

Ning S, Pagano JS, Barber GN. Irf7: activation, regulation, modification and function. Genes Immun. 2011;12:399–414. https://doi.org/10.1038/gene.2011.21.CrossRefPubMedPubMedCentral

63.

Olson BM, Sullivan JA, Burlingham WJ. Interleukin 35: a key mediator of suppression and the propagation of infectious tolerance. Front Immunol. 2013;4:315. https://doi.org/10.3389/fimmu.2013.00315.CrossRefPubMedPubMedCentral

64.

Cernadas M, Lu J, Watts G, Brenner MB. CD1a expression defines an interleukin-12 producing population of human dendritic cells. Clin Exp Immunol. 2009;155:523–33. https://doi.org/10.1111/j.1365-2249.2008.03853.x.CrossRefPubMedPubMedCentral

65.

Cupovic J, Onder L, Gil-Cruz C, Weiler E, Caviezel-Firner S, Perez-Shibayama C, Rülicke T, Bechmann I, Ludewig B. Central nervous system stromal cells control local CD8(+) T cell responses during virus-induced neuroinflammation. Immunity. 2016;44:622–33. https://doi.org/10.1016/j.immuni.2015.12.022.CrossRefPubMed

66.

Steinbach K, Vincenti I, Kreutzfeldt M, Page N, Muschaweckh A, Wagner I, Drexler I, Pinschewer D, Korn T, Merkler D. Brain-resident memory T cells represent an autonomous cytotoxic barrier to viral infection. J Exp Med. 2016;213:1571–87. https://doi.org/10.1084/jem.20151916.CrossRefPubMedPubMedCentral

67.

Wakim LM, Woodward-Davis A, Liu R, Hu Y, Villadangos J, Smyth G, Bevan MJ. The molecular signature of tissue resident memory CD8 T cells isolated from the brain. J Immunol. 2012;189:3462–71.CrossRefPubMed

68.

McNab F, Mayer-Barber K, Sher A, Wack A, O'Garra A. Type I interferons in infectious disease. Nat Rev Immunol. 2015;15:87–103. https://doi.org/10.1038/nri3787.CrossRefPubMed

69.

Greenough TC, Straubhaar JR, Kamga L, Weiss ER, Brody RM, McManus MM, Lambrecht LK, Somasundaran M, Luzuriaga KF. A gene expression signature that correlates with CD8+ T cell expansion in acute EBV infection. J Immunol. 2015;195:4185–97. https://doi.org/10.4049/jimmunol.1401513.CrossRefPubMedPubMedCentral

70.

Pudney VA, Leese AM, Rickinson AB, Hislop AD. CD8+ immunodominance among Epstein-Barr virus lytic cycle antigens directly reflects the efficiency of antigen presentation in lytically infected cells. J Exp Med. 2005;201:349–60.CrossRefPubMedPubMedCentral

71.

Hislop AD, Taylor GS, Sauce D, Rickinson AB. Cellular responses to viral infection in humans: lessons from Epstein–Barr virus. Annu Rev Immunol. 2007;25:587–617.CrossRefPubMed

72.

Jaquiéry E, Jilek S, Schluep M, Meylan P, Lysandropoulos A, Pantaleo G, Du Pasquier RA. Intrathecal immune responses to EBV in early MS. Eur J Immunol. 2010;40:878–87. https://doi.org/10.1002/eji.200939761.CrossRefPubMed

73.

Lossius A, Johansen JN, Vartdal F, Holmøy T. High-throughput sequencing of TCR repertoires in multiple sclerosis reveals intrathecal enrichment of EBV-reactive CD8+ T cells. Eur J Immunol. 2014;44:3439–52. https://doi.org/10.1002/acn3.295.CrossRefPubMed

74.

van Nierop GP, Mautner J, Mitterreiter JG, Hintzen RQ, Verjans GM. Intrathecal CD8 T-cells of multiple sclerosis patients recognize lytic Epstein-Barr virus proteins. Mult Scler. 2016;22:279–91. https://doi.org/10.1177/1352458515588581.CrossRefPubMed

75.

Münz C. Role of human natural killer cells during Epstein-Barr virus infection. Crit Rev Immunol. 2014;34:501–7.CrossRefPubMed

76.

Salvetti M, Giovannoni G, Aloisi F. Epstein-Barr virus and multiple sclerosis. Curr Opin Neurol. 2009;22:201–6.CrossRefPubMed

77.

Baker D, Marta M, Pryce G, Giovannoni G, Schmierer K. Memory B cells are major targets for effective immunotherapy in relapsing multiple sclerosis. EBioMedicine. 2017;16:41–50. https://doi.org/10.1016/j.ebiom.2017.01.042.CrossRefPubMedPubMedCentral

Title: Transcriptional profile and Epstein-Barr virus infection status of laser-cut immune infiltrates from the brain of patients with progressive multiple sclerosis
Authors: Caterina Veroni
Barbara Serafini
Barbara Rosicarelli
Corrado Fagnani
Francesca Aloisi
Publication date: 01-12-2018
Publisher: BioMed Central
Published in: Journal of Neuroinflammation / Issue 1/2018
Electronic ISSN: 1742-2094
DOI: https://doi.org/10.1186/s12974-017-1049-5

At a glance: The STEP trials

Springer Medicine

Transcriptional profile and Epstein-Barr virus infection status of laser-cut immune infiltrates from the brain of patients with progressive multiple sclerosis

Abstract

Background

Methods

Results

Conclusion

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2018

Decreased level of irisin, a skeletal muscle cell-derived myokine, is associated with post-stroke depression in the ischemic stroke population

Mitochondrial damage and “plugging” of transport selectively in myelinated, small-diameter axons are major early events in peripheral neuroinflammation

Laquinimod attenuates inflammation by modulating macrophage functions in traumatic brain injury mouse model

Perturbing chondroitin sulfate proteoglycan signaling through LAR and PTPσ receptors promotes a beneficial inflammatory response following spinal cord injury

Anti-inflammatory and anti-oxidant mechanisms of an MMP-8 inhibitor in lipoteichoic acid-stimulated rat primary astrocytes: involvement of NF-κB, Nrf2, and PPAR-γ signaling pathways

Combined effect of non-bacteriolytic antibiotic and inhibition of matrix metalloproteinases prevents brain injury and preserves learning, memory and hearing function in experimental paediatric pneumococcal meningitis